MA40466A - Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique - Google Patents

Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique

Info

Publication number
MA40466A
MA40466A MA040466A MA40466A MA40466A MA 40466 A MA40466 A MA 40466A MA 040466 A MA040466 A MA 040466A MA 40466 A MA40466 A MA 40466A MA 40466 A MA40466 A MA 40466A
Authority
MA
Morocco
Prior art keywords
treatment
liver disease
fatty liver
glucagon receptor
alcoholic fatty
Prior art date
Application number
MA040466A
Other languages
English (en)
Inventor
In Young Choi
Sang Youn Hwang
Sung Youb Jung
Jin Young Kim
Seung Su Kim
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40466(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA40466A publication Critical patent/MA40466A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une composition pharmaceutique permettant la prévention ou le traitement de stéatose hépatique non-alcoolique comprenant un agoniste double de récepteur de glp-1/glucagon à action prolongée, et un procédé pour prévenir ou traiter la stéatose hépatique non-alcoolique comprenant l'administration de la composition. La composition de la présente invention n'a aucun effet secondaire de prise de poids ou réduit l'effet secondaire de prise de poids, qui est un effet secondaire d'ag
MA040466A 2014-09-16 2015-09-16 Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique MA40466A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20140122862 2014-09-16

Publications (1)

Publication Number Publication Date
MA40466A true MA40466A (fr) 2016-03-24

Family

ID=55533503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040466A MA40466A (fr) 2014-09-16 2015-09-16 Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique

Country Status (26)

Country Link
US (2) US10233230B2 (fr)
EP (1) EP3197483A4 (fr)
JP (2) JP6832273B2 (fr)
KR (3) KR102541971B1 (fr)
CN (1) CN107106660B (fr)
AR (1) AR101896A1 (fr)
AU (3) AU2015318881A1 (fr)
CA (1) CA2960657A1 (fr)
CL (1) CL2017000638A1 (fr)
CO (1) CO2017002689A2 (fr)
CR (1) CR20170129A (fr)
EA (1) EA201790568A1 (fr)
EC (1) ECSP17022931A (fr)
GT (1) GT201700056A (fr)
IL (2) IL251060B (fr)
MA (1) MA40466A (fr)
MX (2) MX2017003438A (fr)
MY (2) MY195618A (fr)
NI (1) NI201700032A (fr)
NZ (1) NZ730799A (fr)
PE (1) PE20170778A1 (fr)
PH (1) PH12017500486A1 (fr)
SG (1) SG11201701841WA (fr)
TW (2) TWI772252B (fr)
WO (1) WO2016043533A1 (fr)
ZA (2) ZA201701847B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012270366C1 (en) 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
NZ739063A (en) 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
TN2017000271A1 (en) 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
PH12018501409B1 (en) 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
CN106046145B (zh) * 2016-04-22 2022-11-04 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
JP7208020B2 (ja) * 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
WO2018143729A1 (fr) 2017-02-03 2018-08-09 한미약품 주식회사 Conjugué de substance bioactive ayant une durabilité améliorée et son utilisation
WO2019085773A1 (fr) * 2017-11-06 2019-05-09 中山大学 Polypeptide agoniste à double cible glp-1r/gcgr analogue d'oxyntomoduline pour le traitement de la fibrose interstitielle pulmonaire idiopathique
CN111278853B (zh) * 2017-11-06 2022-06-21 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
CN111818971A (zh) * 2018-01-03 2020-10-23 梅德瑞斯糖尿病有限责任公司 用于治疗nash和其他紊乱的改进的肽药物
WO2019171352A2 (fr) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Méthodes de traitement de l'obésité non diabétique sévère
US11753455B2 (en) 2018-06-21 2023-09-12 Novo Nordisk A/S Compounds for treatment of obesity
WO2020128967A2 (fr) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Méthodes de traitement de l'obésité non diabétique sévère
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
EP4311578A3 (fr) * 2019-06-28 2024-04-10 Hanmi Pharm. Co., Ltd. Triple agoniste ayant une activité par rapport à tous les récepteurs du glucagon, de glp-1 et de gip pour traitement de maladies hépathiques
WO2021010531A1 (fr) * 2019-07-18 2021-01-21 한미약품 주식회사 Nouveau procédé de préparation d'un conjugué protéique
KR20210103265A (ko) * 2020-02-13 2021-08-23 주식회사 제넥신 신규 비알코올성 지방간염 치료용 약학 조성물
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
WO2021221482A1 (fr) 2020-04-29 2021-11-04 주식회사 원진바이오테크놀로지 Nouveau conjugué de protéine et son utilisation pour la prévention ou le traitement de la stéatohépatite non alcoolique, de l'obésité et du diabète
CN113292646B (zh) * 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022015039A1 (fr) * 2020-07-14 2022-01-20 (주)지아이이노베이션 Protéine de fusion comprenant un peptide-1 de type glucagon et un peptide-2 de type glucagon et utilisation associée
EP4197550A4 (fr) * 2020-08-14 2025-10-08 Hanmi Pharmaceutical Co Ltd Composition pharmaceutique à effet hypotenseur comprenant un activateur triple présentant une activité pour tous les récepteurs du glucagon, de la glp-1, et de la gip
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
US20240307508A1 (en) * 2020-12-22 2024-09-19 Medi & Gene Pharmaceutical composition for preventing or treating alcoholic and nonalcoholic fatty liver disease
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
EP4281464A4 (fr) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions et procédés pour le traitement de troubles métaboliques et hépatiques
WO2022178366A1 (fr) * 2021-02-21 2022-08-25 Spitfire Pharma Llc Agonistes de glp-1r, gip-r et/ou gcgr, formulations et procédés d'utilisation
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN116589536B (zh) * 2023-05-18 2024-01-23 江苏师范大学 一类长效glp-1/gip受体双重激动剂及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999044630A1 (fr) 1998-03-06 1999-09-10 Chugai Seiyaku Kabushiki Kaisha Preparations exemptes de proteines
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (fr) 2003-01-22 2006-10-11 Human Genome Sciences Inc Proteines hybrides d'albumine
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (fr) 2003-10-16 2005-04-21 Compugen Ltd. Variants d'epissage de preproglucagon, de peptide de type glucagon 1 et d'oxyntomoduline
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
EP1853627A2 (fr) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2007100535A2 (fr) 2006-02-22 2007-09-07 Merck & Co., Inc. Dérivés d'oxyntomoduline
BRPI0712383A2 (pt) 2006-06-07 2012-07-10 Human Genome Sciences Inc proteìnas de fusão da albumina
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
KR101545181B1 (ko) 2007-07-27 2015-08-21 바이엘 크롭사이언스 아게 삼원 활성 화합물의 배합물
EP2187910A2 (fr) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Utilisation de band 3 protein (824-829) et/ou melanocyte-stimulating hormone release-inhibiting factor en tant qu'agent thérapeutique pour le traitement d'infection par pseudomonas aeruginosa
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
EP2249853A4 (fr) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d' esters
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
AU2009260302B2 (en) * 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
WO2010013012A2 (fr) 2008-08-01 2010-02-04 Lund University Bioscience Ab Polypeptides inédits et leurs utilisations
EP2344200A2 (fr) 2008-09-19 2011-07-20 Nektar Therapeutics Peptides thérapeutiques modifiés, procédés pour les préparer et les utiliser
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (fr) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
EP2408800B1 (fr) 2009-03-20 2016-05-25 Hanmi Science Co., Ltd. Procédé de préparation d'un conjugué site-spécifié d'un polypeptide physiologiquement actif
WO2010108154A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs peptidiques de kv1.3 sélectifs et puissants
US9150632B2 (en) * 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
AU2010321587A1 (en) * 2009-11-23 2012-06-07 Amylin Pharmaceuticals, Inc. Polypeptide Conjugate
EP2509997B1 (fr) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugués comprenant un échafaudage de substituts d'anticorps présentant des propriétés pharmacocinétiques améliorées
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
US20130143798A1 (en) 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2588126A4 (fr) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp Promédicaments peptidiques à base d'amides de la superfamille du glucagon
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SG191252A1 (en) * 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
AU2012270366C1 (en) 2011-06-17 2017-07-13 Hanmi Science Co., Ltd. A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
BR112013032717A2 (pt) * 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
NZ739063A (en) 2012-11-06 2019-11-29 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途

Also Published As

Publication number Publication date
AR101896A1 (es) 2017-01-18
JP6832273B2 (ja) 2021-02-24
PE20170778A1 (es) 2017-07-04
IL268702B (en) 2020-11-30
KR20230091840A (ko) 2023-06-23
IL251060B (en) 2019-09-26
PH12017500486B1 (en) 2017-08-07
AU2021203106A1 (en) 2021-06-10
IL268702A (en) 2019-09-26
US20170298117A1 (en) 2017-10-19
EP3197483A4 (fr) 2018-05-09
WO2016043533A1 (fr) 2016-03-24
AU2021203106B2 (en) 2024-11-14
KR20160032699A (ko) 2016-03-24
KR102541971B1 (ko) 2023-06-13
TW202233240A (zh) 2022-09-01
SG11201701841WA (en) 2017-04-27
CN107106660B (zh) 2021-10-22
CA2960657A1 (fr) 2016-03-24
PH12017500486A1 (en) 2017-08-07
ZA201903822B (en) 2021-02-24
IL251060A0 (en) 2017-04-30
MX2017003438A (es) 2017-11-13
GT201700056A (es) 2019-08-09
US10435459B2 (en) 2019-10-08
TWI772252B (zh) 2022-08-01
CO2017002689A2 (es) 2017-06-30
KR102762409B1 (ko) 2025-02-05
CR20170129A (es) 2017-05-22
US20190169271A1 (en) 2019-06-06
ECSP17022931A (es) 2018-04-30
CL2017000638A1 (es) 2017-11-03
NZ730799A (en) 2021-07-30
NI201700032A (es) 2017-06-22
JP2021035942A (ja) 2021-03-04
AU2015318881A1 (en) 2017-03-30
CN107106660A (zh) 2017-08-29
KR20250024003A (ko) 2025-02-18
TW201625303A (zh) 2016-07-16
ZA201701847B (en) 2020-10-28
MY178378A (en) 2020-10-09
BR112017004934A2 (pt) 2017-12-12
EP3197483A1 (fr) 2017-08-02
US10233230B2 (en) 2019-03-19
MY195618A (en) 2023-02-02
JP2017529354A (ja) 2017-10-05
AU2024227659A1 (en) 2024-11-14
MX2022007012A (es) 2022-06-17
TWI802396B (zh) 2023-05-11
EA201790568A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
MA40466A (fr) Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique
ZA201608077B (en) Combination, composition, and method of administering the combination or composition to animals
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
IL250196B (en) Solid dosage form composition for oral or sublingual administration of cannabinoids
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
HUE072802T2 (hu) Lokális zsírcsökkentésre alkalmas gyógyszerkészítmény és annak alkalmazása
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
EP3231436A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie métabolique, comprenant des bactéries bacteroides acidifaciens utilisées comme principe actif efficace
TN2016000535A1 (en) Ppar compounds for use in the treatment of fibrotic diseases.
ZA201606199B (en) Compositions and methods for treating diabetes and liver diseases
ZA201704957B (en) Composition for the treatment of hepatic veno-occlusive disease
EP3156055A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies liées à la faiblesse musculaire contenant du butylpyridinium ou un dérivé de celui-ci
EP3285758A4 (fr) Composition de co-cristaux et son utilisation pharmaceutique
ZA201805080B (en) Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
PL2957280T3 (pl) Stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
SG10201912638VA (en) Emulsion composition for skin
PL3313370T3 (pl) Okulistyczna kompozycja farmaceutyczna
PL3142641T3 (pl) Preparaty do leczenia nadczynności tarczycy
IL251392A0 (en) Transformed aromatic compounds and their pharmaceutical preparations for the prevention and treatment of diabetes
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
PL3176164T3 (pl) Izomer optyczny pochodnej 1-tlenku 1,4-benzotiazepiny oraz farmaceutyczna kompozycja wytworzona z jego użyciem
EP3229025A4 (fr) Procédé pour évaluer l'effet thérapeutique d'un agent anti-cancéreux ayant un anticorps anti-cd4 comme ingrédient actif